Stone Summit Wealth LLC Sells 3,025 Shares of Agilent Technologies, Inc. $A

Stone Summit Wealth LLC reduced its stake in Agilent Technologies, Inc. (NYSE:A) by 16.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 15,167 shares of the medical research company’s stock after selling 3,025 shares during the quarter. Stone Summit Wealth LLC’s holdings in Agilent Technologies were worth $2,613,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in A. State Street Corp lifted its stake in Agilent Technologies by 0.7% during the second quarter. State Street Corp now owns 12,854,230 shares of the medical research company’s stock worth $1,710,658,000 after purchasing an additional 89,598 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Agilent Technologies by 2.7% during the second quarter. Wellington Management Group LLP now owns 7,454,686 shares of the medical research company’s stock worth $990,206,000 after buying an additional 198,253 shares during the period. Deutsche Bank AG boosted its position in shares of Agilent Technologies by 17.1% during the second quarter. Deutsche Bank AG now owns 7,008,634 shares of the medical research company’s stock worth $930,957,000 after buying an additional 1,024,516 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Agilent Technologies by 87.4% in the second quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock valued at $695,227,000 after buying an additional 2,440,360 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Agilent Technologies by 9.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,108,764 shares of the medical research company’s stock valued at $240,336,000 after buying an additional 185,223 shares in the last quarter.

Insider Activity

In other news, Director Mikael Dolsten sold 634 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $151.38, for a total transaction of $95,974.92. Following the completion of the transaction, the director directly owned 4,924 shares of the company’s stock, valued at approximately $745,395.12. The trade was a 11.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Key Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Analysts raised their targets: Morgan Stanley increased its target from $175 to $190 and maintained an “overweight” rating, while TD Cowen lifted its target from $180 to $196 and assigned a “buy” rating. The revisions suggest analysts see additional upside based on Agilent’s growth outlook. TD Cowen Adjusts Price Target on Agilent Technologies
• Positive Sentiment: Agilent agreed to acquire Proscia, a pathology software company, for $240 million upfront plus milestone payments, bringing the potential transaction value to approximately $270 million. Proscia’s AI-enabled digital pathology technology could strengthen Agilent’s scientific intelligence and diagnostic capabilities, while expanding its exposure to the growing pathology software market. Agilent to Acquire Proscia
• Positive Sentiment: Market growth provides a favorable backdrop: A new industry report projects the global metabolomics market will expand at a 17.3% compound annual growth rate through 2030. Agilent is identified as one of the key companies positioned to benefit from increased adoption of AI-assisted diagnostics and life-science research tools. Global Metabolomics Market Report 2026
• Neutral Sentiment: Agilent plans to expand its capabilities in China, potentially supporting long-term regional growth. However, the article does not provide specific investment amounts, timelines, or expected financial contributions, leaving the near-term earnings impact uncertain. Agilent to Expand Capabilities in China
• Negative Sentiment: The Proscia transaction introduces acquisition costs and execution risks, and milestone payments could increase the ultimate purchase price. Investors will likely watch for regulatory approvals, integration progress, and evidence that the deal contributes meaningfully to revenue and earnings.

Agilent Technologies Stock Up 0.2%

Agilent Technologies stock opened at $171.66 on Wednesday. The firm has a market capitalization of $48.40 billion, a P/E ratio of 28.27, a P/E/G ratio of 2.61 and a beta of 1.21. The company has a current ratio of 2.05, a quick ratio of 1.56 and a debt-to-equity ratio of 0.50. Agilent Technologies, Inc. has a twelve month low of $108.35 and a twelve month high of $177.05. The stock’s fifty day simple moving average is $157.13 and its 200-day simple moving average is $136.41.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%. The firm had revenue of $1.88 billion during the quarter, compared to analyst estimates of $1.84 billion. During the same period last year, the business posted $1.37 earnings per share. Agilent Technologies’s revenue was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, equities analysts expect that Agilent Technologies, Inc. will post 6.20 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 28th. Stockholders of record on Tuesday, October 6th will be paid a $0.2550 dividend. This represents a $1.02 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Tuesday, October 6th. Agilent Technologies’s dividend payout ratio (DPR) is presently 20.08%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Wall Street Zen downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Citigroup raised their target price on Agilent Technologies from $185.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, August 27th. TD Cowen lifted their target price on Agilent Technologies from $180.00 to $196.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings upgraded shares of Agilent Technologies from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Finally, Jefferies Financial Group initiated coverage on shares of Agilent Technologies in a research note on Thursday, July 9th. They set a “hold” rating and a $135.00 price target on the stock. Fifteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $173.65.

About Agilent Technologies

Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.

The company’s products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.